People with multiple sclerosis (MS) of African descent had higher levels of inflammatory B-cells in the fluid around the…
Articles by Marisa Wexler, MS
More activity among certain immune cells, as well as differences in immune signaling molecules, iron regulation, and fat metabolism, may…
People with a higher genetic risk for multiple sclerosis (MS) were seen to have detectable differences in their gut…
Achieving NEDA — no evidence of disease activity — after two years of treatment was not common among people with…
The overall financial impact of changes in treatment and delayed diagnoses for people with multiple sclerosis (MS) in Canada…
Brain atrophy (shrinkage) in people with multiple sclerosis (MS) begins on average more than five years before disease…
Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six…
New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis…
Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or…
Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly…
Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in…
A clinical trial that was testing if treatments for multiple sclerosis (MS) could be discontinued in people with stable…
A personalized dosing schedule for Tysabri (natalizumab) that aims to maintain blood levels of the drug above a certain…
Five of six people with secondary progressive multiple sclerosis (SPMS) treated with an experimental oral therapy called OCH saw…
A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as…
Infection with the Epstein-Barr virus (EBV) may prime the immune system to accidentally attack a brain protein called ANO2,…
Six months of treatment with the experimental oral therapy vidofludimus calcium (IMU-838) led to significant reductions in a marker…
Most disability worsening events happen independent of relapse activity across all types of multiple sclerosis (MS), including clinically…
Problems with sexual dysfunction are a concern for multiple sclerosis (MS) patients of all ages, but the issues tend…
People with multiple sclerosis (MS) in the United Kingdom are less likely to be on disease-modifying treatments (DMTs)…
The expression of a viral protein known as W-Env leads to the inflammatory activation of brain cells and impairs myelin…
Among multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab), most of the disability worsening they experience is not…
Over more than a decade of treatment with Lemtrada (alemtuzumab), relapse rates were low and about half of people…
For older adults with multiple sclerosis (MS) who have highly active disease, most neurologists recommend starting treatment with a…
People with multiple sclerosis (MS) under treatment with Ocrevus (ocrelizumab) commonly experience fluctuations in the severity of their…
Researchers have identified nearly two dozen genes that help to control the movement of immune cells into the brain and…
Taking supplements of the sugar molecule N-acetylglucosamine, known as GlcNAc, was found to decrease markers of inflammation in people with…
Note: This story was updated Sept. 15, 2023, to clarify ANK-700 was developed based on the preclinical work described in…
A new statistical method could help to more accurately capture changes in disability severity for people with multiple sclerosis…
A protein called Daam2 helps to regulate the activity of cells in the brain that make myelin, the fatty covering…